Moderna, Inc. (NASDAQ:MRNA) | WebDisclosure

Basculer en Français

8315	Companies
115922	Keywords
55962	Articles
62833	Press releases

Home
Companies
Moderna, Inc.

BRIEF

published on 06/28/2024 at 13:05, 4 months 27 days ago

EMA Committee Recommends Marketing Authorization for Moderna's RSV Vaccine

Moderna MRNA Vaccine RSV EMA Marketing Authorization
PRESS RELEASE

published on 06/28/2024 at 13:00, 4 months 27 days ago

EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Marketing Authorization Of Moderna’s RSV Vaccine, mRESVIA(R)
Moderna, Inc. receives positive opinion from EMA CHMP for mRESVIA mRNA-1345 vaccine for RSV in adults aged 60+. The decision from the European Commission is awaited

Moderna Inc. RSV Vaccine MRESVIA EMA CHMP MRNA-1345
BRIEF

published on 06/13/2024 at 13:05, 5 months 12 days ago

Moderna annonce des données positives d'efficacité de phase 3 pour l'ARNm-1283, le vaccin COVID-19 de nouvelle génération de la société

Moderne ARNm-1283 Vaccin Contre Le Covid-19 Essai De Phase 3 Données D'efficacité
BRIEF

published on 06/13/2024 at 13:05, 5 months 12 days ago

Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine

COVID-19 Vaccine Moderna Phase 3 Trial MRNA-1283 Efficacy Data
PRESS RELEASE

published on 06/13/2024 at 13:00, 5 months 12 days ago

Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine
Moderna's mRNA-1283 demonstrates non-inferior COVID-19 vaccine efficacy compared to Spikevax in Phase 3 trial. Higher efficacy in adults observed. Positive interim results reported

COVID-19 Vaccine Moderna Phase 3 Trial MRNA-1283 Spikevax
BRIEF

published on 06/10/2024 at 12:35, 5 months 16 days ago

Moderna annonce des données positives de phase 3 pour un vaccin combiné contre la grippe et le COVID-19

Moderne Vaccin Contre Le Covid-19 Essai De Phase 3 ARNm-1083 Grippe
BRIEF

published on 06/10/2024 at 12:35, 5 months 16 days ago

Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19

COVID-19 Vaccine Moderna Phase 3 Trial MRNA-1083 Influenza
PRESS RELEASE

published on 06/10/2024 at 12:30, 5 months 16 days ago

Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19
Moderna's mRNA-1083 Phase 3 trial for flu and COVID combination vaccine elicits strong immune responses in adults 50+ & 65+. Promising results may reshape respiratory virus vaccination

COVID-19 Moderna Phase 3 Trial MRNA-1083 Flu
BRIEF

published on 06/07/2024 at 16:35, 5 months 18 days ago

Moderna dépose une demande auprès de la FDA pour le vaccin JN.1 ciblant la COVID-19

FDA Moderne COVID 19 Spikevax Variante JN.1
BRIEF

published on 06/07/2024 at 16:35, 5 months 18 days ago

Moderna Files FDA Application for JN.1 Targeting COVID-19 Vaccine

FDA COVID-19 Moderna Spikevax JN.1 Variant

Accesswire

Published on 11/26/2024 at 12:00, 58 minutes ago

Indian American, Rajan Hooda, PhD., Solves 4,500-Year-Old Mystery of How Egyptian Pyramids Were Built in Groundbreaking New Theory
Published on 11/26/2024 at 10:40, 2 hours 18 minutes ago

Chow Tai Fook Jewellery Reports Resilient Operating Profit as it Grows to HK$6.8 billion in 1HFY2025 Amid Challenging Market Environment
Published on 11/26/2024 at 09:05, 3 hours 53 minutes ago

Q2 Metals Significantly Expands the Cisco Lithium Property in James Bay, Quebec, Canada
Published on 11/26/2024 at 08:00, 4 hours 58 minutes ago

High Grade Gold from Maiden Drilling Results at the Nanoq Project
Published on 11/26/2024 at 02:15, 10 hours 43 minutes ago

Alphinat Awarded Contract SSO Platform for an Ontario Municipality

View all ACCESSWIRE

EQS Group

Published on 11/26/2024 at 12:47, 10 minutes ago

LR Health & Beauty SE further increases growth trend in the third quarter
Published on 11/26/2024 at 12:45, 13 minutes ago

EQS-Adhoc: LR Health & Beauty SE: Publication of figures for the third quarter of 2024 and adjustment of the forecast for the 2024 financial year
Published on 11/26/2024 at 12:30, 28 minutes ago

Form 8.3 - LOYS AG: Learning Technologies Group plc
Published on 11/26/2024 at 12:30, 28 minutes ago

Immunic, Inc. to Participate in Investor Conference in December
Published on 11/26/2024 at 12:17, 40 minutes ago

EQS-Adhoc: Brenntag CEO Dr. Christian Kohlpaintner will not extend his contract beyond 2025

Les Echos

Published on 11/26/2024 at 08:30, 4 hours 28 minutes ago

Cie du Bois Sauvage: Terugkoop van eigen aandelen – Week van 18/11/2024 tot 22/11/2024
Published on 11/26/2024 at 08:30, 4 hours 28 minutes ago

Cie du Bois Sauvage : Rachat d’actions propres – semaine du 18/11/2024 au 22/11/2024
Published on 11/26/2024 at 08:30, 4 hours 28 minutes ago

Cie du Bois Sauvage: Buy back of own shares – week from 18/11/2024 to 22/11/2024
Published on 11/26/2024 at 07:57, 5 hours 1 minute ago

Neoen and Equinix sign their first PPA in Italy supporting decarbonization of the local grid
Published on 11/26/2024 at 07:57, 5 hours 1 minute ago

Neoen et Equinix signent leur premier PPA en Italie en faveur de la décarbonation du réseau électrique

View all LES ECHOS COMFI WIRE